Related Experiment Videos

Rheumatoid arthritis: radiographic progression is getting milder

Eswar Krishnan, James F Fries

The Journal of Rheumatology

|January 5, 2005

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Annals of the rheumatic diseases·2019

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Arthritis research & therapy·2019

Favorable Cardiovascular Health at Young and Middle Ages and Dementia in Older Age-The CHA Study.

Journal of the American Heart Association·2018

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.

Lancet (London, England)·2018

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.

Arthritis & rheumatology (Hoboken, N.J.)·2018

Varying the item format improved the range of measurement in patient-reported outcome measures assessing physical function.

Arthritis research & therapy·2017

See all related articles